Extended lymphadenectomy for locally advanced and recurrent rectal cancer by unknown
ORIGINAL ARTICLE
Extended lymphadenectomy for locally advanced and recurrent
rectal cancer
Panagiotis A. Georgiou1,2 & S. Mohammed Ali1,2 & Gina Brown3 &
Shahnawaz Rasheed1,2 & Paris P. Tekkis1,2
Accepted: 18 November 2016 /Published online: 27 January 2017
# The Author(s) 2017. This article is published with open access at Springerlink.com
Abstract
Purpose The purpose of this study is to assess the value of
extended (lateral) lymphadenectomy (EL) in the operative
management of locally advanced and recurrent rectal cancer.
Methods Patients that underwent exenterative surgery for lo-
cally advanced or recurrent rectal cancer between 2006 and
2009 were included in the study. A decision for EL was taken
at the local multidisciplinary meeting based on the radiologi-
cal findings. Perioperative and oncological outcomes were
assessed and compared between the EL and non-EL group
prospectively.
Results Forty-one consecutive patients were included in the
study (EL = 17). The median age was 57 (40–71) for EL and
66 (39–81) years for non-EL. Of patients, 27 (EL = 13) and 14
(EL = 4) underwent pelvic exenteration and abdominosacral
resection, respectively. Twelve (EL = 7) patients were diag-
nosed with locally advanced primary rectal cancer. Thirty-one
(EL = 12) patients received neoadjuvant radiotherapy. The
median intraoperative time, blood loss and hospital stay were
9 h (3–13), 1.5 l (0.3–7) and 14 days (12–72), respectively, for
the EL group, and 8 h (4–15), 1.6 l (0.25–17) and 14 days (10–
86), respectively, for the non-EL (p ≥ 0.394). Morbidity was
similar between the two groups (EL = 4, non-EL = 9;
p = 0.344). Complete tumour resection (R0) was achieved in
30 (73.17%) patients, 12 (70.58%) in the EL group and 18
(75%) in the non-EL group (p = 0.649). There was no signif-
icant difference in 5-year survival (EL = 60.7%, non-
EL = 75.2%; p = 0.447), local recurrence (EL = 53.6%, non-
EL = 65.4%; p = 0.489) and disease-free survival
(EL = 53.6%, non-EL = 51.4%; p = 0.814).
Conclusions The present study demonstrated that EL does not
provide a statistically significant advantage in survival or re-
currence rates, for patients with locally advanced primary or
recurrent rectal cancer.
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Introduction
The presence of lateral pelvic lymph node metastases in rectal
cancer was first reported in the 1950s [1]. Nodal involvement
has subsequently been demonstrated to adversely affect the
prognosis [2–7], resulting in higher incidence of local recur-
rence and reduced survival [2, 3, 5, 6]. Lateral pelvic lymph
node metastases (along the obturator, internal iliac and medial
aspect of the external iliac artery) have been reported to be
involved in 10–25% of patients operated for rectal cancer
[1–3]. Based on these findings, surgeons in Japan have
adopted the technique of lateral pelvic sidewall (extended)
lymphadenectomy (EL) to supplement conventional rectal
surgery, aiming to reduce local recurrence rates and improve
the cancer-specific survival [8–10].
There has been an on-going debate about the value of lateral
pelvic sidewall lymphadenectomy in the management of pri-
mary rectal cancer. A recent meta-analysis [11] demonstrated a
higher likelihood of poor quality of life in terms of sexual and
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urinary dysfunction in patients undergoing extended lymphad-
enectomy, without any significant oncological benefit except in
stage III low rectal cancers. The authors concluded that the
value of lateral pelvic sidewall should be further investigated
in the setting of a randomised controlled study. It was felt that
extended lymphadenectomy should be compared to neoadju-
vant chemoradiotherapy, which has been shown to decrease the
risk of local recurrence by up to 61% [12] although without any
significant improvement in the overall survival.
In a series of 93 patients who underwent a pelvic exenter-
ation for locally advanced rectal cancer [13], it was demon-
strated that lateral pelvic sidewall lymph node involvement
was significantly associated with reduced survival (p = 0.01)
compared to patients without any lymph node metastases.
Lateral local recurrence (including lateral pelvic sidewall
lymph node involvement) following surgery for rectal cancer
has been reported to be about 27% of all patients who present
with local recurrence [14, 15]. It is, therefore, a common form
of local failure that requires aggressive management either in
the form of chemoradiotherapy or excision of the lymph
nodes. Failure to address thismay result in disease progression
within the adjacent iliac vessels or the sciatic nerve increasing
the likelihood of the disease becoming irresectable [16].
In the group of patients with locally advanced primary and
recurrent rectal cancers that require exenterative pelvic sur-
gery with curative intent, the value of extended lymphadenec-
tomy has not been investigated. To the authors’ knowledge,
this is the first study that aims to assess the oncological benefit
of performing lateral sidewall pelvic lymphadenectomy in pa-
tients who undergo surgery beyond the boundaries of a stan-
dard total mesorectal excision (TME).
Methods
Study design and subjects
Data were extracted from a prospective database of consecutive
patients who underwent exenterative pelvic surgery for locally
advanced primary and recurrent rectal cancer between
March 2006 and October 2009. Routine data recorded in the
database included (1) patient demographics; (2) operative de-
tails; (3) neoadjuvant treatment and staging; (4) tumour histo-
pathology and (5) follow-up data, including the cause of death
when applicable and local recurrence data. Data were collect-
ed in a modified Microsoft® Excel/SPSS spreadsheet. The
decision for lateral pelvic sidewall lymphadenectomy was tak-
en either during the local multidisciplinary meetings based on
radiological imaging evidence of sidewall nodes involved by
tumour or intraoperative evidence of lateral pelvic sidewall
lymph node metastasis. This was an observational study with-
out any influence on the management of patients and it was
approved by the regional cancer network.
Inclusion and exclusion criteria
All adult patients (age >18 years) undergoing pelvic
exenterative surgery for locally advanced primary or recurrent
rectal cancer were included. Patients with metastatic cancer
(TNM Stage IV) or those undergoing palliative procedures
were excluded.
End points and outcomes
The principle end points were local recurrence of rectal can-
cer, diagnosed by radiological or histopathological examina-
tion and cancer-specific survival (CSS). Perioperative out-
comes such as intraoperative time, estimated blood loss,
length of stay and morbidity were assessed between the EL
and non-EL groups. The intraoperative time was defined as
the length of time for surgery and did not include anaesthetic
time. Similarly, estimated blood loss was recorded in litres lost
during surgery. Length of stay was defined as the time taken to
discharge from the first postoperative day. Morbidity was de-
fined as any unexpected event that deviated from the ideal
postoperative recovery that either delayed discharge, required
treatment with antibiotics, additional invasive procedures (e.g.
percutaneous drainage) or further surgery.
Extended lymphadenectomy technique
Following dissection and mobilisation of the sigmoid and de-
scending colon, the inferior mesenteric artery and vein were
ligated and divided high (in primary resections and recurrent
operations if not done previously). The small bowel was
reflected and protected to allow exposure of the pelvis to enable
the initiation of the lateral dissection. The retroperitoneum was
dissected at the level of the bifurcation of the aorta exposing the
origin of the common iliac arteries. The lateral lymph node
dissection was performed the same way as it was previously
described in 1989 by Moriya [10]. The bifurcation of the com-
mon iliac artery was identified and the internal iliac artery was
traced down towards the lower pelvis. The lateral pelvic lymph-
adenectomywas performed either en bloc with the internal iliac
vessels or by preserving them, depending on the proximity of
tumour to the internal iliac artery. This decision was often guid-
ed by preoperative assessment at the local colorectal multidis-
ciplinary team meeting.
The dissection of the lateral pelvic sidewall lymph nodes
commenced with the dissection of the internal iliac vessels
from the medial structures. The branches of the internal iliac
vessels were identified, ligated and divided as close to their
origin as possible. For the cases that the tumour was close to
the iliac artery, the lateral pelvic sidewall lymphadenectomy
was performed en bloc with the resected specimen including
the unilateral internal iliac artery and preservation of the su-
perior vesical artery and the obturator nerve, if possible.
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When the lateral pelvic sidewall lymphadenectomywas per-
formed to remove lesions suspicious for malignancy or isolated
malignant lateral lymph nodes, the nerve preserving approach
was utilised (conventional lateral dissection) [10]. The speci-
men was resected en bloc with the tumour while the lateral
pelvic sidewall spaces were opened between the lateral aspect
of the internal iliac vessels and the pelvic sidewall, exposing the
lateral lymphatic tissue and enabling the harvesting of lymph
nodes. Using the nerve preserving technique, the obturator
nerve and internal iliac vessels with their branches were pre-
served without disturbing the sacral nerve plexuses.
With the completion of the lateral pelvic sidewall dissec-
tion and the abdominal mobilisation of the specimen, depend-
ing on the extent of the tumour, a pelvic exenterative proce-
dure was performed with or without the removal of the sacrum
(abdominosacral resection).
Statistics
Categorical demographic characteristics were compared using
chi-squared test; age and continuous variables were compared
using ANOVA. Survival curves were obtained using the
Kaplan-Meier method, which allows for estimation of out-
comes in datasets in which censored data are present. The
log-rank test was used to compare the two groups. Censored
patients were considered those who had incomplete follow-up
or those who died during follow-up before reaching 5 years
without experiencing the outcomes of interest. Local recurrence
and disease-free survival curves were estimated in relation to
both EL and non-EL groups. Comparisons were considered
statistically significant at a probability value of p < 0.05.
Data were entered in the Statistical Package for Social
Sciences (SPSS Inc., Chicago, IL), which was also used for
the statistical analysis.
Results
Demographic data (Table 1)
A total of 41 (28 males) patients with a median age of 64 (39–
81) were included in the present study. Twelve (29.27%) pa-
tients with locally advanced primary and 29 (70.73%) patients
with recurrent rectal cancer underwent exenterative pelvic sur-
gery. Lateral pelvic sidewall lymphadenectomy was per-
formed in 17 (41.4%) patients. The patients in the EL group
were younger (median age 57 (40–71)) compared to the non-
EL group (median 66 (39–81); p = 0.042). There was no
statistically significant difference in the gender distribution
between the two groups (p = 0.467). Thirty-one (75.6%) pa-
tients were treated with neoadjuvant radiotherapy; 12 and 19
were in the EL and non-EL groups, respectively. This differ-
ence did not reach statistical significance (p = 0.529). All
patients had open surgery with 14 (34.15%) of them undergo-
ing an abdominosacral resection with the remainder having
other pelvic exenterative procedures. There was no statistical-
ly significant difference in the type of surgery that was per-
formed in the two groups (p = 0.192). Four plastic reconstruc-
tions with flaps were performed in EL group and 13 in the
non-EL group. This difference approached statistical signifi-
cance (p = 0.051).
Perioperative outcomes (Table 2)
The median intraoperative time (IOT) was 9 (3–13) and 8 h (4–
15) for the EL and non-EL groups, respectively. The median
intraoperative blood loss was 1.5 (0.3–7) and 1.6 l (0.25–17)
for the EL and non-EL groups. The median length of stay was
15 days for both groups. Neither of the above perioperative
outcomes reached statistical significance (p ≥ 0.344). A total
of 4/17 (23.52) complications were observed in the EL group
and 9/24 (37.5%) in the non-EL group. This difference was not
statistically significant between the two groups either
(p = 0.344). For the EL group, there were two patients with
Clavien-Dindo [17] grade 4 complications and two with grade
3. For Non-EL group, there were one grade 4, five grade 3, two
grade 2 and one grade 1. There was no significance between the
two groups (p = 0.367). There was no perioperative mortality.
Oncological outcomes (Table 3)
Curative resections were achieved in 30 (73.17%) patients: 12
(70.58%) in the EL group and 18 (75%) in the non-EL group.
There were 8 (19.51%) patients with microscopic residual
disease (R1) at the resection margins, 3 (17.64%) in the EL
group and 5 (20.83%) in the non-EL group. In 3 (7.32%)
patients, there was macroscopic residual disease at the resec-
tion margins (R2), 2 (11.76%) in the EL and 1 (4.17%) in the
non-EL group. There was no statistically significant difference
between the two groups in terms of tumour clearance
(p = 0.649). There were 6 (35.29%) patients with malignant
lateral pelvic sidewall lymph nodes. Other histopathological
data are shown in Table 1. There was no significant difference
between the two groups in terms of the histopathology either
(p ≥ 0.292). Two patients responded fully to neoadjuvant ra-
diotherapy, one in each group.
Since three patients had R2 resections, 38 patients were
included for recurrence and disease-free survival. There
were 6 patients in each group that were diagnosed with
local recurrence following potentially curative surgery
(R0 and R1). There was no statistically significant differ-
ence between the two groups (p = 0.367). All local recur-
rences were diagnosed within 3 years from surgery. There
were two local recurrences per year in the EL group
(Table 4). There were four local recurrences within the first
year of surgery in the non-EL group, one in the second and
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one in the third. Distant metastases were diagnosed in two
(13.33%) and six (26.08%) patients in the EL and non-EL
groups, respectively (all patients). This difference did not
reach statistical significance (p = 0.292).
Overall survival, disease-free survival and local
recurrence-free survival curves were generated using the
Kaplan-Meier method (Fig. 1). The two groups were com-
pared using the log-rank test. One (1/41; 2.44%) patient in
the non-EL group was lost to follow-up 2 months after
curative surgery (R0). The longest follow-up was
70 months with median follow-up of 33 months. For over-
all survival, (Fig. 1a) 88.2% (SE = 7.8%), 81.9%
(SE = 9.5%) and 60.7% (SE = 12.7%) patients were alive
at 12, 24 and 36 months, respectively, following surgery
in the EL group; 95.8% (SE = 4.1%), 82.1% (SE = 8.2%)
and 75.2% (SE = 9.9%) patients were alive at 12, 24 and
36 months, respectively, in the non-EL group. There was
no statistically significant difference between the two
groups (p = 0.447).
For the disease- and local recurrence-free survival
curves, patients with either complete (R0) or residual mi-
croscopic disease at the margins (R1) were included. A
total of 78.6% (SE = 11%), 71.4%(SE = 12.1%) and
53.6% (SE = 14.2%) were disease free at 12, 24 and
36 months from surgery in the EL group, respectively;
66.7% (SE = 10.3%), 60% (SE = 11.2%) and 51.4%
(SE = 12.5%) were disease free at 12, 24 and 36 months
following surgery in the non-EL group, respectively
(Fig. 1b). This difference did not achieve statistical sig-
nificance (p = 0.814).
A total of 78.6% (SE = 11%), 71.4% (SE = 12.1%) and
53.6% (SE = 14.2%) were local recurrence-free at 12, 24
and 36 months from surgery, respectively, in the EL
group; 81% (SE = 8.6%), 74.7% (SE = 9.9%) and
65.4% (SE = 12.3%) were local recurrence-free after 12,
24 and 36 months, respectively, following surgery in the
non-EL group (Fig. 1c). This difference did not reach
statistical significance (p = 0.489).
Table 1 Demographic data
Total (n = 41) EL (n = 17) Non-EL (n = 24) p
Age (mean, SD) 64 (39–81) 57 (40–71) 66 (39–81) 0.042
Sex (M/F) 28/13 11/6 17/7 0.678
Recurrent cancer 29 10 19 0.158
Primary cancer 12 7 5
Radiotherapy 31 12 19 0.529
Surgery 0.228
ASR 14 4 10
PE 27 13 14
Flaps 17 4 13 0.051
Histopathology type 0.791
Adenocarcinoma 37 15 22
Signet cell 2 1 1
Differentiation 0.636
Well/moderate 20 7 13
Poor/mucinous 19 9 10
PNI 19 6 13 0.242
Vascular invasion 20 7 13 0.433
n number, EL extended lymphadenectomy, non-EL non-extended lymphadenectomy, p probability of obtaining a
test statistic at least as extreme as the one that was actually observed, M male, RT radiotherapy, F female, PE
pelvic exenteration, APER abdominoperineal excision of the rectum, SCC squamous cell carcinoma, PNI peri-
neural invasion
Table 2 Perioperative outcomes
Total (n = 41) EL (n = 17) Non-EL (n = 24) p
IOT (median, range) 8 (3–15) 9 (3–13) 8 (4–15) 0.903
Blood loss (median, range) 1.6 (0.25–17) 1.5 (0.3–7) 1.6 (0.25–17) 0.394
LOS (median, range) 15 (10–86) 15 (12–72) 14 (10–86) 0.887
Morbidity 13 4 9 0.344
n number, EL extended lymphadenectomy, non-EL non-extended lymphadenectomy, IOT intraoperative time,
LOS length of stay, EL extended lymphadenectomy, ASR abdominosacral resection
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Discussion
This was an observational study that investigated the val-
ue of lateral pelvic sidewall lymphadenectomy in a group
of consecutive patients who underwent exenterative sur-
gery for locally advanced primary and recurrent rectal
cancer. The present study demonstrated no statistically
significant differences between EL and non-EL regarding
perioperative (intraoperative time and blood loss, morbid-
ity and length of hospital stay) and oncological (clearance
rates, recurrences, overall and disease-free survival) out-
comes. However, the patients in the EL group were youn-
ger than the patients in the non-EL group.
Intraoperative time and blood loss always have concerned
surgeons when planning extended lymphadenectomy in pri-
mary rectal cancer patients. Intraoperative time and blood loss
have been previously shown to increase by 76 min and
500 ml, respectively, when lateral pelvic sidewall lymphade-
nectomy was performed for primary rectal cancer [11]. The
present study investigated the value of EL in patients that
underwent exenterative pelvic surgery for locally advanced
primary and recurrent rectal cancer and demonstrated no sub-
stantial difference between the two groups. Exenterative pel-
vic surgery alone is known to last longer and to result in
significant intraoperative blood loss [16, 13]. This is reflected
by the results of this study and may explain the absence of
significant difference between the two groups.
Overall survival, local recurrence-free and disease-free sur-
vival rates were demonstrated to have no significant difference
between the EL and non-EL group. However, the difference
in the overall and local recurrence-free survival was large and
cannot be overlooked on the basis of statistical significance,
with the non-EL group having a more favourable outcome.
This may be a reflection of a more advanced and challenging
to treat disease, for the patients with tumour invading the
lateral pelvic sidewall. These findings need to be interpreted
with caution though due to the small size of this study. A
prospective randomised study with a larger number of patients
may provide the power to answer this question. All recur-
rences occurred within 3 years following surgery which is
consistent with the results published by other studies that re-
port the majority of the recurrences were diagnosed within
3 years from surgery [18, 19] although tumours may recur
up to 10 years following surgery [19].
Neoadjuvant (chemo)radiotherapy has been shown to re-
duce local failure significantly following surgery for recurrent
rectal cancer (p = 0.036) but has not been demonstrated to
influence overall survival and metastasis-free survival [20].
For primary rectal cancer, published studies suggested that ra-
diotherapy might have a similar result to EL in regards to over-
all and disease-free survival [21, 22]. For recurrent and locally
advanced rectal cancers, the evidence is not clear with regards
to the value of radiotherapy. At the authors’ Institute, neoadju-
vant chemoradiotherapy is always used for patients that under-
go exenterative surgery for primary and recurrent rectal cancer
when it is not contraindicated. It is also of high importance to
emphasise that further research investigating the role of chemo-
radiotherapy is essential in this group of patients.
Lateral pelvic sidewall lymphadenectomy has an adverse
impact on the quality of life of patients, in terms of urinary
[23–25] and sexual [21, 26, 27] function as previously demon-
strated for primary rectal cancer, as the autonomic nerves in the
region are at high risk or are sacrificed to achieve the optimum
oncological outcome. Therefore, a significant amount of time
is required preoperatively to discuss the benefits and risks of
extended lymphadenectomy with patients due to undergoing
surgery for primary cancer surgery. The quality of life of
Table 3 Oncological outcomes
Total (n = 41) EL (n = 17) Non-EL (n = 24) p
Clearance 0.649
R0 30 (73.17%) 12 (70.58%) 18 (75%)
R1 8 (19.51%) 3 (17.64%) 5 (20.83%)
R2 3 (7.32%) 2 (11.76%) 1 (4.17%)
Local recurrence 12/38 (31.58%) 6/15 (40%) 6/23 (26.08%) 0.367
Distant recurrence 8 (19.51%) 2 (11.76%) 6 (25%) 0.292
n number, EL extended lymphadenectomy, non-EL non-extended lymphadenectomy, R0 complete tumour resec-
tion, R1 microscopic residual tumour at the margins, R2 macroscopic residual tumour at the margins or
irresectable tumour, LR local recurrence, DR distant recurrence
Table 4 Recurrences diagnosed per year
1 year 2 years 3 years 5 years
Local recurrence
EL 2 2 2 0
Non-EL 4 1 1 0
Distant recurrence
EL 1 1 0 0
Non-EL 4 1 1 0
EL ex t ended lymphadenec tomy, non -EL non- ex t ended
lymphadenectomy
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patients undergoing exenterative surgery has also been dem-
onstrated to be adversely affected [28]. This is due to the
sacrifice of the nerves along with other intrapelvic organs
due to their close relationship or proximity to the tu-
mour. Therefore, en bloc dissection of the lateral pelvic lymph
nodes may be preferred to nerve preservation lymphadenecto-
my as it very rarely influences the postoperative quality of life
in this group of patients. A recent study [29] that aimed to
measure the quality of life for longer-term disease-free survivors
after pelvic exenteration demonstrated comparable results to
low anterior resection or abdominoperineal excision of the
rectum for primary rectal cancer. They showed a low
score for the physical component but similar scores in the
mental component of the scoring form.
In the present study, the patients that underwent lateral
pelvic sidewall lymphadenectomy were younger than the pa-
tients who did not. However, age is not a factor in the decision
process to perform this procedure. When a patient is deemed
fit for exenterative surgery, it is extremely unlikely that ex-
tended lymphadenectomy will be rejected as an option, if re-
quired. Exenterative pelvic surgery carries significant risks
with the morbidity ranging up to more than 50% of the oper-
ated patients [30–32, 18, 16]. Therefore, patients are thor-
oughly examined and tested to ensure their fitness to endure
the operation and minimise morbidity.
A decision for lateral pelvic sidewall lymphadenectomy
was taken in this series of patients when there was either
radiological or intraoperative evidence of malignant lateral
pelvic sidewall lymph nodes, or the tumour invaded the lateral
pelvic compartment and had to be removed en bloc with the
lymph nodes. Tumours within the lateral pelvic compartment
are considered to have poorer prognosis [13, 18, 19]. The fact
that younger patients had to undergo lateral pelvic sidewall
lymphadenectomy may indicate that their tumour was more
aggressive, a factor that may need to be taken into account
when considering young patients for exenterative pelvic sur-
gery. However, further studies investigating the tumour histo-
pathology of these patients are essential to conclude this.
Lateral compartment recurrences, including the lateral
lymph nodes, can be up to 26.7% of the patterns of local
recurrence [33, 14] and demonstrated to be a factor that ad-
versely affects survival following surgery [14, 33]. This can be
partially a result of the high risk of incomplete tumour resec-
tion when it extends within the lateral pelvic compartment.
Moore et al. [18] demonstrated that pelvic sidewall recurrence
was a strong determinant of incomplete resection (p = 0.004).
Similarly, Sagar et al. [19], in a series of 40 patients that
underwent abdominosacral resection for recurrent rectal can-
cer, demonstrated that 15/20 (75%) patients with non-curative
resections had lateral compartment recurrence. This led them
to consider extending their resection margins in future cases
when preoperative MR imaging identifies tumour within the
lateral compartment. Performing lateral pelvic sidewall
Survival 
Months 0 6 12 18 24 30 36 42 48 54 60
No 24 22 22 17 14 14 8 6 3 2 0
Yes 17 16 15 14 12 9 7 4 3 2 2
Disease-free survival
Months 0 6 12 18 24 30 36 42 48 54 60
No 23 19 14 12 9 9 5 3 1 1 0
Yes 15 13 11 9 8 6 6 3 3 2 2
Local Recurrence free Survival
Months 0 6 12 18 24 30 36 42 48 54 60
No 23 20 17 14 11 11 6 4 2 2 0















































































Fig. 1 Survival curves. a Kaplan-Meier Survival curve—overall surviv-
al. b Kaplan-Meier Survival curve—disease-free survival. c Kaplan-
Meier Survival curve—local recurrence-free survival. EL extended
lymphadenectomy
338 Int J Colorectal Dis (2017) 32:333–340
lymphadenectomy might be a method of extending the lateral
resection margins and may be considered in patients when
aiming curative resection.
One of the strengths of the present study was that the pa-
tients were managed and operated by the same multidisciplin-
ary team thus eliminating bias. One of the limitations of this
study is the relatively small number of patients that were in-
cluded requiring a careful interpretation of the results of this
study. Exenterative surgery or this group of patients is per-
formed on about 250 patients a year in the UK and several
years will be required to gather adequate data to increase the
power of the study significantly. A second limitation may be
that a single colorectal surgeon, albeit with experience in pel-
vic cancer surgery, performed these procedures. Thus, the re-
ported outcomes might not be representative since there is
likely to be some variance between surgeons.
Conclusion
The present study demonstrated that lateral pelvic sidewall
lymphadenectomy does not offer a statistically significant ad-
vantage regarding the oncological and perioperative outcomes
in patients that undergo exenterative surgery for locally ad-
vanced primary and recurrent rectal cancer, and that it is safe
to perform. However, the study size is small, and therefore
these results should be interpreted with caution.
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